Junichi Soh

7.4k total citations · 1 hit paper
211 papers, 5.5k citations indexed

About

Junichi Soh is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Junichi Soh has authored 211 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 155 papers in Pulmonary and Respiratory Medicine, 92 papers in Oncology and 59 papers in Molecular Biology. Recurrent topics in Junichi Soh's work include Lung Cancer Treatments and Mutations (104 papers), Lung Cancer Diagnosis and Treatment (55 papers) and Lung Cancer Research Studies (30 papers). Junichi Soh is often cited by papers focused on Lung Cancer Treatments and Mutations (104 papers), Lung Cancer Diagnosis and Treatment (55 papers) and Lung Cancer Research Studies (30 papers). Junichi Soh collaborates with scholars based in Japan, United States and Canada. Junichi Soh's co-authors include Shinichi Toyooka, Hiromasa Yamamoto, Shinichiro Miyoshi, Katsuyuki Kiura, Hiroaki Asano, Hiroshi Date, Kazuhiko Shien, Adi F. Gazdar, Kazunori Tsukuda and John D. Minna and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Junichi Soh

201 papers receiving 5.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments

2021 167 citations T. Koga, Kenichi Suda et al. Journal of Thoracic Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Junichi Soh Japan	40	3.2k	2.5k	2.5k	1.5k	410	211	5.5k
José Javier Sánchez Spain	38	2.8k 0.9×	3.0k 1.2×	3.0k 1.2×	1.6k 1.1×	537 1.3×	90	6.0k
Hisayuki Shigematsu Japan	31	5.3k 1.6×	3.0k 1.2×	4.2k 1.7×	1.5k 1.1×	439 1.1×	77	7.2k
Kazuko Sakai Japan	41	2.3k 0.7×	2.0k 0.8×	2.7k 1.1×	1.3k 0.9×	727 1.8×	245	5.4k
Antonio Marchetti Italy	36	2.9k 0.9×	2.5k 1.0×	2.7k 1.1×	2.0k 1.3×	624 1.5×	111	5.8k
Antonio Chella Italy	39	3.5k 1.1×	1.6k 0.6×	2.9k 1.2×	1.2k 0.8×	340 0.8×	130	5.5k
Samuel E. DePrimo United States	28	2.5k 0.8×	2.7k 1.1×	2.2k 0.9×	1.3k 0.9×	496 1.2×	40	5.3k
Umberto Malapelle Italy	43	2.8k 0.9×	2.1k 0.8×	2.6k 1.0×	2.4k 1.7×	836 2.0×	265	5.7k
Noemı́ Reguart Spain	41	2.6k 0.8×	2.5k 1.0×	2.9k 1.1×	875 0.6×	341 0.8×	175	5.5k
Mark S. Huberman United States	30	3.3k 1.0×	1.2k 0.5×	3.0k 1.2×	778 0.5×	353 0.9×	80	4.5k
Gilda da Cunha Santos Canada	28	3.4k 1.0×	1.3k 0.5×	2.6k 1.0×	1.1k 0.7×	404 1.0×	76	5.1k

Countries citing papers authored by Junichi Soh

Since Specialization

Citations

This map shows the geographic impact of Junichi Soh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Junichi Soh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Junichi Soh more than expected).

Fields of papers citing papers by Junichi Soh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Junichi Soh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Junichi Soh. The network helps show where Junichi Soh may publish in the future.

Co-authorship network of co-authors of Junichi Soh

This figure shows the co-authorship network connecting the top 25 collaborators of Junichi Soh. A scholar is included among the top collaborators of Junichi Soh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Junichi Soh. Junichi Soh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Suda, Kenichi, Akira Hamada, Toshio Fujino, et al.. (2025). Efficacy of Conventional and Novel Tyrosine Kinase Inhibitors for Uncommon EGFR Mutations—An In Vitro Study. Cells. 14(17). 1386–1386.

Suzuki, Satoshi, Nobuhiro Izumi, Kazuya Kishimoto, et al.. (2025). Pulmonary Lobectomy for Chronic Pulmonary Vein Occlusion after Catheter Ablation for Atrial Fibrillation: A Case Report and Literature Review. Surgical Case Reports. 11(1). n/a–n/a.

Suda, Kenichi, Akira Hamada, Shuta Ohara, et al.. (2024). Potential Utility of a 4th-Generation EGFR-TKI and Exploration of Resistance Mechanisms—An In Vitro Study. Biomedicines. 12(7). 1412–1412. 6 indexed citations

Ohara, Shuta, Kenichi Suda, Akira Hamada, et al.. (2024). Clinical factors associated with high PD‐L1 expression in patients with early‐stage non‐small cell lung cancer. Thoracic Cancer. 15(31). 2229–2234. 1 indexed citations

Soh, Junichi, Shinichi Toyooka, Yasushi Shintani, et al.. (2022). Limited resection for stage IA radiologically invasive lung cancer: a real-world nationwide database study. European Journal of Cardio-Thoracic Surgery. 62(1). 22 indexed citations

Hamada, Akira, Junichi Soh, Akito Hata, et al.. (2021). Phase II Study of Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage IIIA-B (Discrete N2) Non–small-cell Lung Cancer: SQUAT trial (WJOG 12119L). Clinical Lung Cancer. 22(6). 596–600. 12 indexed citations

Soh, Junichi, Kazuhiko Shien, Takeshi Kurosaki, et al.. (2020). Effectiveness of scheduled intravenous acetaminophen in the postoperative pain management of video-assisted thoracic surgery. Surgery Today. 51(4). 589–594. 4 indexed citations

Ohara, Shuta, Kenji Tomizawa, Shigeki Shimizu, et al.. (2019). Primary pulmonary mucosa-associated lymphoid tissue lymphoma with amyloid light chain-type amyloidosis. SHILAP Revista de lepidopterología. 5(1). 105–105.

Namba, Kei, Kazuhiko Shien, Yuta Takahashi, et al.. (2018). Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR -Mutant Non–Small Cell Lung Cancer Cells. Molecular Cancer Research. 17(2). 499–507. 71 indexed citations

10.

Torigoe, Hidejiro, Kazuhiko Shien, Takahiro Yoshioka, et al.. (2018). Therapeutic strategies for afatinib‐resistant lung cancer harboring HER2 alterations. Cancer Science. 109(5). 1493–1502. 20 indexed citations

11.

Yamamoto, Hiromasa, Hirotaka Kanzaki, Ken Suzawa, et al.. (2017). Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer. PLoS ONE. 12(2). e0171356–e0171356. 29 indexed citations

12.

Shien, Kazuhiko, Shinichi Toyooka, Hiromasa Yamamoto, et al.. (2013). Acquired Resistance to EGFR Inhibitors Is Associated with a Manifestation of Stem Cell–like Properties in Cancer Cells. Cancer Research. 73(10). 3051–3061. 223 indexed citations

13.

Zhang, Wei, Junichi Soh, Victor Stastny, et al.. (2013). CDKN2A/p16 Inactivation Mechanisms and Their Relationship to Smoke Exposure and Molecular Features in Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 8(11). 1378–1388. 74 indexed citations

14.

Yamamoto, Hiromasa, Koichiro Higasa, Masakiyo Sakaguchi, et al.. (2013). Novel Germline Mutation in the Transmembrane Domain of HER2 in Familial Lung Adenocarcinomas. JNCI Journal of the National Cancer Institute. 106(1). djt338–djt338. 88 indexed citations

15.

Sunaga, Noriaki, David S. Shames, Luc Girard, et al.. (2011). Knockdown of Oncogenic KRAS in Non–Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy. Molecular Cancer Therapeutics. 10(2). 336–346. 135 indexed citations

16.

Kubo, Takafumi, Shinichi Toyooka, Kazunori Tsukuda, et al.. (2011). Epigenetic Silencing of MicroRNA-34b/c Plays an Important Role in the Pathogenesis of Malignant Pleural Mesothelioma. Clinical Cancer Research. 17(15). 4965–4974. 92 indexed citations

17.

Soh, Junichi, Naoki Okumura, William W. Lockwood, et al.. (2009). Oncogene Mutations, Copy Number Gains and Mutant Allele Specific Imbalance (MASI) Frequently Occur Together in Tumor Cells. PLoS ONE. 4(10). e7464–e7464. 179 indexed citations

18.

Pratilas, Christine A., Aphrothiti J. Hanrahan, Ensar Halilovic, et al.. (2008). Genetic Predictors of MEK Dependence in Non–Small Cell Lung Cancer. Cancer Research. 68(22). 9375–9383. 195 indexed citations

19.

Kubo, Takafumi, Hiromasa Yamamoto, William W. Lockwood, et al.. (2008). MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. International Journal of Cancer. 124(8). 1778–1784. 117 indexed citations

20.

Toyooka, Shinichi, Akiko Uchida, Hisayuki Shigematsu, et al.. (2007). The Effect of Gefitinib on B-RAF Mutant Non-small Cell Lung Cancer and Transfectants. Journal of Thoracic Oncology. 2(4). 321–324. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact